Report workspace tools

NCT05785195UNKNOWNanonymous

Study on the Mechanism of Inhaled Nitric Oxide in the Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) Complicated With Pulmonary Hypertension

Sponsor

Source record

Ting YANG

Phase

Source record

NA

Modality

AI-normalized

gene therapy

Target

AI-normalized

Nitric Oxide Generation and Delivery System

Indication / condition

AI-normalized

Chronic Obstructive Pulmonary Disease

Intervention

Source record

Nitric Oxide Generation and Delivery System

Source & freshness

Source record

NCT ID

NCT05785195

Original source

ClinicalTrials.gov

Source last updated

May 15, 2023

Ingested at

May 21, 2026

Internal sync

May 23, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT05785195

Title

Study on the Mechanism of Inhaled Nitric Oxide in the Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) Complicated With Pulmonary Hypertension

Sponsor

Ting YANG

Status

UNKNOWN

Phase

NA

Condition raw

Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension

Condition normalized

Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension

Modality raw

gene therapy

Modality normalized

gene therapy

Target raw

Nitric Oxide Generation and Delivery System

Target normalized

Nitric Oxide Generation and Delivery System

Interventions

Nitric Oxide Generation and Delivery System

Public preview

Source record

There is a lack of effective treatments for chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension. Previous studies have found that inhaled nitric oxide (iNO) can reduce pulmonary artery pressure and improve exercise capacity in COPD with pulmonary hypertension patients. However, the specific mechanism is unclear. The study aims to evaluate pulmonary ventilation/perfusion, pulmonary artery pressure, oxygenation, symptoms and quality of life in COPD with pulmonary hypertension patients after short-term treatment with iNO. Observing a series of pathophysiological changes caused by the treatment of pulmonary hypertension with iNO in COPD, the investigators hope to provide new theoretical basis and research ideas.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account

Create a free account first, then unlock a single report, buy credits or subscribe.